Hims & Hers Health announced plans to expand to Canada in 2026. Hims will offer generic copies of semaglutide drugs in Canada as Novo Nordisk loses patent protection. Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a maintenance fee in 2019. The Hers website arranged on a laptop in New York, US, on Wednesday, Feb. 12, 2025. Gabby Jones | Bloomberg | Getty Images
Hims & Hers Health announced Wednesday it will offer generic semaglutide in Canada as Novo Nordisk‘s patent on its branded drugs Ozempic and Wegovy is set to expire in January.
“Canada is a major opportunity to show what affordable, high-quality weight loss care can look like,” said Andrew Dudum, co-founder and CEO of Hims & Hers, in a press release.